Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Gianfranco Ferraccioli, J. S. Smolen, P. Emery, W. Samborski, F. Berenbaum, O. R. Davies, W. Koetse, O. Purcaru, B. Bennett, H. Burkhardt

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Original languageEnglish
Pages (from-to)843-850
Number of pages8
JournalANNALS OF THE RHEUMATIC DISEASES
Volume74
DOIs
Publication statusPublished - 2015

Keywords

  • Adolescent
  • Anti-TNF
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Certolizumab Pegol
  • DMARDs (biologic)
  • Disease Activity
  • Double-Blind Method
  • Drug Therapy, Combination
  • Immunoglobulin Fab Fragments
  • Immunosuppressive Agents
  • Maintenance Chemotherapy
  • Methotrexate
  • Middle Aged
  • Polyethylene Glycols
  • Remission Induction
  • Rheumatoid Arthritis
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Fingerprint Dive into the research topics of 'Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this